Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds antigen or epitope whose amino acid sequence is...
Reexamination Certificate
2001-05-08
2008-11-25
Belyavskyi, Michail A (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds antigen or epitope whose amino acid sequence is...
C424S184100
Reexamination Certificate
active
07455836
ABSTRACT:
The present invention relates generally to a method for the treatment and prophylaxis of inflammatory conditions. The present invention is predicated in part on the identification of cells of the monocyte/macrophage lineage being critical for inflammation and, in particular, chronic inflammation. In accordance with the present invention, it is proposed that the reduction in levels of monocyte/macrophage-type cells and/or a reduction in the production of inflammatory and pro-inflammatory mediators by these cells, especially locally, is effective in reducing inflammatory conditions. The present invention further provides animal models useful for screening for reducing levels of monocyte/macrophage-type cells and/or reducing the production of inflammatory and pro-inflammatory mediators of these cells.
REFERENCES:
patent: 5444153 (1995-08-01), Goss et al.
patent: 5475087 (1995-12-01), Seelig et al.
patent: 5662609 (1997-09-01), Slepian
patent: 5747032 (1998-05-01), Metcalf et al.
patent: 5837460 (1998-11-01), Von Feldt et al.
patent: 5962447 (1999-10-01), Rogers et al.
patent: 5962477 (1999-10-01), Mak
patent: 6200567 (2001-03-01), Lopez et al.
patent: 6482403 (2002-11-01), Sim et al.
patent: 2002/0141994 (2002-10-01), Devalaraja et al.
patent: 11244595 (1999-09-01), None
patent: JA 2000198799 (2000-07-01), None
patent: 9728190 (1997-08-01), None
patent: 0009561 (2000-02-01), None
patent: WO 00/09561 (2000-02-01), None
Mikayama et al. PNAS, 1993. 90: 10056-10060.
Burgess et al J Cell Biol. 111:2129-2138, 1990.
Bost et al. Immunol. Invest. 1988; 17:577-586.
Bendayan J. Histochem. Cytochem. 1995; 43: 881-886.
Janeway et al. Immunobiology, Third Edition, 1999, pp. 650-651.
Cook A.D., Braine E.L., Campbell I.K., Rich M.J., Hamilton J.A. (2001)Arthritis Res.“Blockade of Collagen-Induced Arthritis Post-Onset by Antibody to Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF): Requirement for GM-CSF in the Effector Phase of Disease” 3(5): 293-8.
Yang Y.H., Hamilton J.A. (2001)Arthritis Rheum.“Dependence of Interleukin-1-Induced Arthritis on Granulocyte-Macrophage Colony-Stimulating Factor” 44(10): 2458-60.
Campbell I.K., Rich M.J., Bischof R.J., Hamilton J.A. (2000)J. Leukoc. Biol.“The Colony-Stimulating Factors and Collagen-Induced Arthritis: Exacerbation of Disease by M-CSF and GM-CSF and Requirement for Endogenous M-CSF” 68(1): 144-50.
Nagata M., Yamamoto H., Tabe K., Sakamoto Y., Matsuo H. (2000)Int. Arch. Allergy Immunol.“Eosinophil-Adhesion-Inducing Activity Produced by Antigen-Stimulated Mononuclear Cells Involves GM-CSF” 122 Suppl 1:15-9.
Vasunia K.B., Miller M.L., Puga A., Baxter C.S. (1994)Carcinogenesis“Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) is Expressed in Mouse Skin in Response to Tumor-Promoting Agents and Modulates Dermal Inflammation and Epidermal Dark Cell Numbers” 15(4): 653-60.
Williamson, D.J. et al., The detection and initial characterization of colony-stimulating factors in synovial fluid, Clinical & Experimental Immunology 72:67-73, 1988.
Xu, W.D. et al., Cytokines in chronic inflammatory arthritis. II. Granulocyte-macrophage colony-stimulating factor in rheumatoid synovial effusions. J Clin Invest 83:876-882, 1989.
Leizer, T. et al. Cytokine regulation of colony-stimulating factor production in cultured human synovial fibroblasts: I. Induction of GM-CSF and G-CSF production by interleukin-1 and tumor necrosis factor. Blood 76:1989-1996, 1990.
Alvaro-Gracia J. et al., Cytokines in chronic inflammatory arthritis. VI. Analysis of the synovial cells involved in granulocyte-macrophage colony-stimulating factor production and gene expression in rheumatoid arthritis and its regulation by IL-1 and tumor necrosis factor-alpha. J Immunol 146:3365-3371, 1991.
De Vries, G. et al., Flare-up of rheumatoid arthritis during GM-CSF treatment after chemotherapy. Lancet 338:517-518, 1991.
Hazenberg, B. et al., Correction of granulocytopenia in Felty's syndrome by granulocyt3- macrophage colony-stimulating factor. Simultaneous induction of interleukin-6 release and flare-up of the arthritis. Blood 74:2769-270, 1989.
Lubbe, A.S. et al., Improvement of pneumonia and arthritis in Felty's syndrome by treatment with granulocyte-macrophage colony-stimulating factor (GM-CSF). Blut 61:379-380, 1990.
Kaiser, U. et al., Felty's syndrome: favorable response to granulocyte-macrophage colony-stimulating factor in the acute phase. Acta Haematol 87:190-194, 1992.
Krishnaswamy, G. et al., Resolution of the neutropenia of Felty's syndrome by longterm administration of recombinant granulocyte colony stimulating factor. J Rheumatol 23:763-765, 1996.
Campbell, I.K. et al., Granulocyte-macrophage colony stimulating factor exacerbates collagen induced arthritis in mice. Ann Rheum Dis 56:364-368, 1997.
Metcalf, D., The Florey Lecture, 1991. The colony-stimulating factors: discovery to clinical use. Philos Trans R Soc Lond B Biol Sci 333:147-173, 1991.
Robertson, F.M. et al., Granulocyte-macrophage colony stimulating factor gene expression and function during tumor promotion. Carcinogenesis 15:1017-1029, 1994.
Vasunia, K.B. et al., Granulocyte-macrophage colony-stimulating factor (GM-CSF) is expressed in mouse skin in response to tumor-promoting agents and modulates dermal inflammation and epidermal dark cell numbers. Carcinogenesis 15:653-660, 1994.
Hercus, T. et al., Specific Human Granulocyte-Macrophage Colony-Stimulating Factor Antagonists. PNAS 91:5838-5842, 1994.
Kinne, R.W. et al., Macrophages in rheumatoid arthritis. Arthritis Res 2:189-202, 2000.
Stanley, E. et al., Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology. Proc Natl Acad Sci U S A 91:5592-5596, 1994.
Paine, R. et al., Impaired functional activity of alveolar macrophages from GM-CSF-deficient mice. Am J Physiol Lung Cell Mol Physiol 281:L1210-1218, 2001.
Dranoff, G. et al., Involvment of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis. Science 264:713-716, 1994.
Coyle, A.J. et al., Interleukin-4 is required for the induction of lung Th2 mucosal immunity. Am J Respir Cell Mol Biol 13:54-59, 1995.
Finkelman, F.D. et al., Anti-cytokine antibodies as carrier proteins. Prolongation of in vivo effects of exogeneous cytokines by injection of cytokine-anti-cytokine antibody complexes. J Immunol 151:1235-1244, 1993.
Sato, T.A. et al., Recombinant soluble murine IL-4 receptor can inhibit or enhance IgE responses in vivo. J Immunol 150:2717-2723, 1993.
Else, K.J. et al., Cytokine-mediated regulation of chronic intestinal helminth infection. J Exp Med 179:347-351, 1994.
Beavitt, S.-J.E. et al., Lyn-Deficient Mice Develop Severe, Persistent Asthma: Lyn Is a Critical Negative Regulator of Th2 Immunity, The Journal of Immunology, 2005, 175: 1867-1875.
Campbell, I.K. et al., Protection from Collagen-Induced Arthritis in Granulocyte-Macrophage Colony-Stimulating Factor-Deficient Mice, The Journal of Immunology, 1998, 161:3639-3644.
Campbell, I.K. et al., The colony-stimulating factors and collagen-induced arthritis: exacerbation of disease by M-CSF and G-CSF and requirement for endogenous M-CSF, Journal of Leukocyte Biology, vol. 68, Jul. 2000, 144-150.
Campbell, I.K. et al., Humanarticular Caritilage and Chondrocytes Produce Hemopoietic Colony-Stimulating Factors in Culture in Response to IL-1, The Journal of Immunology Vo. 147. 1238-1246, No. 4, Aug. 15, 1991.
Firestein, G.S. et al., Cytokines in Chronic Inflammatory Arthritis, The Rockefeller University Press vol. 168, Nov. 1988, 1573-1586.
Nakajima, H. et al., The effect of treatment with interferon-gamma on type II collagen-induced arthritis, Clin. exp. Immunol. 81, 441-445, 1990.
Joosten, L.A.B. et al., Dual Role of IL-12 in Early and Late Stages of Murine Collagen Type II Arthritis, The Journal of Immunology, 1997, 159: 4094-4102.
Szeliga, J. et al., IL-12 promotes cellular but not humoral type II collagen-specific Th1-type responses in C57BL/6 and B10. Q mice and fails
Anderson Gary Peter
Campbell Ian Keith
Hamilton John
Belyavskyi Michail A
Knobbe Martens Olson & Bear LLP
The University of Melbourne
LandOfFree
Method of treatment and agents useful for same does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treatment and agents useful for same, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treatment and agents useful for same will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4023211